Cooperative agreement signed by the Republic of Indonesia and Sakata Seed Corporation

Sakata Seed Corporation and the Indonesian government have formally agreed on the utilization of indigenous genetic resources for the further development of SunPatiens. This agreement is based on the Convention on Biological Diversity (CBD).

 

SunPatiens, offered by Sakata Seed Corporation, is an assortment of garden flowers that was developed in line with the principles of CBD, in collaboration with the Indonesian Agency for Agricultural Research and Development (IAARD) for access to its native resources. SunPatiens uses the breeding material of Indonesia’s native species of Impatiens. 

 

In the early 2000s, IAARD and Sakata made a basic agreement for the utilization of this native species and Sakata has been conducting research and development ever since. Starting with this basic agreement, Sakata has been using Indonesian collection of genetic resources of Impatiens by applying material transfer agreement following CBD.

 

SunPatiens was commercially launched in 2006. Sakata pays a share of the SunPatiens royalty proceeds to the Indonesian government and, in addition, performs technology transfer as a non-monetary benefit. 

 

In 2014, the two parties updated the collaboration and implemented a joint research project based on new national measures. In 2016, both parties will continue to collaborate and will proceed with joint research of Indonesia and Sakata that will further contribute to the development, the utilization of genetic resources and the conservation and utilization of biological diversity.